Tryptase-positive mast cells and angiogenesis in keloids: A new possible post-surgical target for prevention

Updates in Surgery

Volumn 65, Issue 1, 2012, Pages 53-57

  Ammendola, Michele ^a   Zuccalà, Valeria ^a   Patruno, Rosa ^b   Russo, Emilio ^a   Luposella, Maria ^a   Amorosi, Andrea ^a   Vescio, Giuseppina ^a   Sammarco, Giuseppe ^a   Montemurro, Severino ^b   De Sarro, Giovambattista ^a   Sacco, Rosario ^a   Ranieri, Girolamo ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Angiogenesis; Keloids; Mast cells; Treatment; Tryptase

Indexed keywords

EID: 84874638055     PISSN: 2038131X     EISSN: 20383312     Source Type: Journal    
DOI: 10.1007/s13304-012-0183-y     Document Type: Article

References (43)

1. Fisseler-Eckhoff A, Rothstein D, Muller KM (1996) Neovascularisation in hyperplastic, metaplastic and potentially preneoplastic lesions of the bronchial mucosa. Virchows Arch 429:95-100
2. Folkman J (1996) Tumor angiogenesis and tissue factor. Nat Med 2:209-215
3. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, Ranieri G, Miceli R, Cheresh DA (1998) Vascular integrin alpha (v) beta3: a new prognostic indicator in breast cancer. Clin Cancer Res 4:2625-2634
4. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13:1845-1857
5. Beer TW, Baldwin HC, Goddard JR, Gallagher PJ, Wright DH (1998) Angiogenesis in pathological and surgical scars. Hum Pathol 29(11):1273-1278
6. Fujiwara M, Muragaki Y, Ooshima A (2005) Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity. Arch Dermatol Res 297(4):161-169
7. Bux S, Madaree A (2010) Keloids show regional distribution of proliferative and degenerate connective tissue elements. Cells Tissues Organs 191(3):213-234
8. Patruno R, Arpaia N, Gadaleta CD, Passantino L, Zizzo N, Misino A, Lucarelli NM, Catino A, Valerio P, Ribatti D, Ranieri G (2009) VEGF concentration from plasma activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. J Cell Mol Med 13(3):555-561
9. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13:1211-1218
10. Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minischetti M, Marzullo A, Herken R, Roncali L, Dammacco F (1999) Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 79:451-455
11. Norrby K (2002) Mast cells and angiogenesis. APMIS 110:355-371
12. Kankkunen JP, Harvima IT, Naukkarinen A (1997) Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer 72:385-388
13. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, Gruber BL (1997) Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 99:2691-2700
14. Somasundaran P, Ren G, Nagar H, Kraemer D, Mendoza L, Michael LH, Caughey GH, Entman ML, Frangogiannis NG (2005) Mast cell tryptase may modulate endothelial cell phenotype in healing myocardial infarcts. J Pathol 205:102-111
15. Ribatti D, Ranieri G, Nico B, Benagiano V, Crivellato E (2011) Tryptase and chymase are angiogenic in vivo in the chorioallantoic membrane assay. Int J Dev Biol 55(1):99-102
16. Kashiwase Y, Morioka J, Inamura H, Yoshizawa Y, Usui R, Kurosawa M (2004) Quantitative analysis of mast cells in benign and malignant breast lesions. Immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Int Arch Allergy Immunol 134:199-205
17. Mangia A, Malfettone A, Rossi R, Paradiso A, Ranieri G, Simone G, Resta L (2011) Tissue remodelling in breast cancer: human mast cells tryptase as an initiator of myofibroblast differentiation. Histopathology 58(7):1096-1106
18. Ranieri G, Grammatica L, Patruno R, Zito AF, Valerio P, Iacobellis S, Gadaleta C, Gasparini G, Ribatti D (2007) A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. J Cell Mol Med 11:362-368
19. Ranieri G, Labriola A, Achille G, Florio G, Zito AF, Grammatica L, Paradiso A (2002) Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma. Int J Oncol 21:1317-1323
20. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montomery K, Chi JT, van de Rijn M, Botstein D, Brown PO (2004) Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2(2):E7
21. Mogili NS, Krishnaswamy VR, Jayaraman M, Rajaram R, Venkatraman A, Korrapati PS (2012) Altered angiogenic balance in keloids: a key to therapeutic intervention. Transl Res 159:182-189
22. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Werb Z, Caughey GH, Hanahan D (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13:1382-1397
23. Nico B, Mangieri D, Crivellato E, Vacca A, Ribatti D (2008) Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev 17:19-22
24. Ribatti D, Nico B, Maxia C, Longo V, Murtas D, Mangieri D, Perra MT, De Giorgis M, Piras F, Crivellato E, Sirigu P (2007) Neovascularization and mast cells with tryptase activity increase simultaneously in human pterygium. J Cell Mol Med 11:585-589
25. Hallgren J, Estrada S, Karlson U, Alving K, Pejler G (2001) Heparin antagonists are potent inhibitors of mast cell tryptase. Biochemistry 40:7342-7439
26. Fajardo I, Pejler G (2003) Human mast cell beta-tryptase is a gelatinase. J Immunol 171(1493):1499
27. Itoh Y, Sendo T, Oishi R (2005) Physiology and pathophysiology of proteinase-activated receptors (PARs): role of tryptase/PAR-2 in vascular endothelial barrier function. J Pharmacol Sci 97:14-19
28. Shpacovitch VM, Brzoska T, Buddenkotte J, Stroh C, Sommerhoff CP, Ansel JC, Schulze-Osthoff K, Bunnett NW, Luger TA, Steinhoff M (2002) Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappaB in human dermal microvascular endothelial cells. J Invest Dermatol 118:380-385
29. 2+-independent phospholipase A2 in bladder microvascular endothelial cells. Am J Physiol Renal Physiol 288:F714-F721
30. Sendo T, Sumimura T, Itoh Y, Goromaru T, Aki K, Yano T, Oike M, Ito Y, Mori S, Nishibori M, Oishi R (2003) Involvement of proteinase-activated receptor-2 in mast cell tryptase-induced barrier dysfunction in bovine aortic endothelial cells. Cell Signal 15:773-781
31. Matej R, Mandakova P, Netikova I, Pouckova P, Olejar T (2007) Proteinase-activated receptor-2 expression in breast cancer and the role of trypsin on growth and metabolism of breast cancer cell line MDA MB-231. Physiol Res 56:475-484
32. Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J (2006) Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 66:307-314
33. Liu Y, Mueller BM (2006) Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochem Biophys Res Commun 344:1263-1270
34. Ranieri G, Passantino L, Patruno R, Passantino G, Jirillo F, Catino A, Mattioli V, Gadaleta C, Ribatti D (2003) The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy. Oncol Rep 10:1189-1193
35. Yano H, Kinuta M, Tateishi H, Nakano Y, Matsui S, Monden T, Okamura J, Sakai M, Okamoto S (1999) Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer 2:26-32
36. Takanami I, Takeuchi K, Naruke M (2000) Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88:2686-2692
37. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST (2006) Mast cells and cutaneous malignancies. Mod Pathol 19:149-159
38. Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P (2003) Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 33:420-425
39. Yodavudh S, Tangjitgamol S, Puangsa-art S (2008) Prognostic significance of microvessel density and mast cell density for the survival of Thai patients with primary colorectal cancer. J Med Assoc Thai 91:723-732
40. Ibaraki T, Muramatsu M, Takai S, Jin D, Maruyama H, Orino T, Katsumata T, Miyazaki M (2005) The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. Eur J Cardiothorac Surg 28:617-621
41. Peng SH, Deng H, Yang JF, Xie PP, Li C, Li H, Feng DY (2005) Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. World J Gastroenterol 11:6521-6524
42. Erba F, Fiorucci L, Pascarella S, Menegatti E, Ascenzi P, Ascoli F (2001) Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug. Biochem Pharmacol 61:271-276
43. Mori S, Itoh Y, Shinohata R, Sendo T, Oishi R, Nishibori M (2003) Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci 92:420-423